Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

SmallCapGrowth Jun. 1 at 3:07 PM

$BCTX showing what investors want to see: 👉 Durable survival in late-stage cancer 👉 Biomarkers validating response 👉 Early Phase 3 momentum building In a space where options are limited, long-term survivor cohorts matter. #Biotech #ASCO2026 NEWS: https://bit.ly/3Se0RRi

0 · Reply

SmallCapGrowth Jun. 1 at 2:47 PM

BriaCell Therapeutics Corp ( $BCTX ): CANCER STOCK NEWS: $BCTX delivers at AS... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177658440 via @Investors_Hub

0 · Reply

JediGreen Jun. 1 at 2:21 PM

$BCTX how much was trodelvy sold for - Google Search https://www.google.com/search?q=how+much+was+trodelvy+sold+for&sca_esv=5f802be1e67c425f&source=hp&ei=CZUdapunCu-mruEPkdrdkAc&biw=430&bih=721&oq=how+much+was+trodelvy&gs_lp=EhFtb2JpbGUtZ3dzLXdpei1ocCIVaG93IG11Y2ggd2FzIHRyb2RlbHZ5KgIIADIFECEYoAEyBRAhGKABMgUQIRigATIFECEYoAEyBhAAGBYYHjIFECEYnwVI29UCUJsMWJjIAnANeACQAQCYAaABoAGtGKoBBTE0LjE1uAEByAEA-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&sclient=mobile-gws-wiz-hp#lfId=ChxjMe

0 · Reply

TWBXX Jun. 1 at 2:15 PM

$BCTX Head‑to‑Head Reality Check Trodelvy (Gilead) — 3L+ MBC Median OS: ~12–13 months 12‑month survival: ~35–40% Toxicity: High (neutropenia, diarrhea, alopecia) Discontinuation rate: Meaningful Mechanism: ADC (TROP‑2), cytotoxic payload Bria‑IMT (BriaCell) — Phase 2, Phase 3 regimen Median OS: 16.6 months 12‑month survival: ~44–55% 24‑month survival: ~26–27% Toxicity: Very low TWiST/QoL: Better than chemo Mechanism: Immune‑activating cellular therapy + CPI

0 · Reply

SmallCapGrowth Jun. 1 at 1:58 PM

CANCER STOCK NEWS: $BCTX delivers at ASCO 2026 ✅ 55% 1-year survival ✅27% 2-year survival ✅Heavily pre-treated metastatic breast cancer This is the kind of dataset that can re-rate a biotech. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV

0 · Reply

DARKP00L Jun. 1 at 1:56 PM

$BCTX 07:43 on Jun. 01 2026 BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2 #tradeideas

0 · Reply

Kirubin Jun. 1 at 1:11 PM

$BCTX Endless money black hole! $2S coming up then RS again🫡🐏🐏🐏🐏👏🏽👏🏽

1 · Reply

Kirubin Jun. 1 at 1:08 PM

$BCTX done!

0 · Reply

SmallCapVoice Jun. 1 at 12:26 PM

BriaCell $BCTX reported positive data at ASCO 2026, highlighting 55% 1-year survival and 27% 2-year survival in heavily pre-treated metastatic breast cancer patients using its Phase 3-selected Bria-IMT™ regimen. Early Phase 3 data also showed meaningful quality-of-life benefits and encouraging biomarker results. https://www.globenewswire.com/news-release/2026/06/01/3304255/0/en/briacell-presents-positive-clinical-data-at-asco-2026.html

0 · Reply

JediGreen Jun. 1 at 12:17 PM

$BCTX Wounder if we will see 4s filed this week.

2 · Reply

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 15 hours ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 6 days ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 6 days ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 6 days ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 10 days ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 10 days ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 10 days ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 17 days ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 17 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 18 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 18 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 19 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 19 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 20 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 25 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 25 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 26 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 5 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 5 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 6 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 6 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 2 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 3 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 4 months ago

Market Cap	26.39M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	145,600
Avg Vol	203,346
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	62%
Beta	1.26
Analysts	Strong Buy
Price Target	$40.00